Please login to the form below

Not currently logged in
Email:
Password:

American Heart Association meeting

This page shows the latest American Heart Association meeting news and features for those working in and with pharma, biotech and healthcare.

AZ says target of $45bn sales by 2023 still achievable

AZ says target of $45bn sales by 2023 still achievable

The product has new cardiovascular outcomes data from the DECLARE-TIMI 58 trial – a must-have for diabetes therapies now – which is due for presentation at the American Heart Association (AHA) ... It will be followed by additional studies in patients

Latest news

  • Amgen's Repatha unclogs blocked arteries, says study Amgen's Repatha unclogs blocked arteries, says study

    At the American Heart Association (AHA) annual meeting this week, lead study author Stephen Nichols of the University of Adelaide in Australia reported that adding a monthly Repatha shot to daily ... The results have also been published in the Journal of

  • Sanofi plans 18 new product launches by 2020 Sanofi plans 18 new product launches by 2020

    These include cholesterol-lowering antibody alirocumab (now given the proposed trade name of Praluent) - fresh from encouraging new data presented at the American Heart Association meeting - as well a vaccine against ... the company will be keen to

  • PCSK9 inhibitor alirocumab works in statin-intolerance PCSK9 inhibitor alirocumab works in statin-intolerance

    PCSK9 inhibitor alirocumab works in statin-intolerance. Sanofi and Regeneron’ s drug impresses at American Heart Association meeting. ... The ODYSSEY ALTERNATIVE trial - reported at the American Heart Association (AHA) meeting in Chicago this week -

  • Merck's ezetimibe has 'modest' benefit when added to statins Merck's ezetimibe has 'modest' benefit when added to statins

    Results presented at the American Heart Association (AHA) meeting showed that 32.7% of Vytorin-treated patients suffered a major cardiovascular event over a median seven-year follow-up period, compared

  • US FDA deems Novartis' heart failure candidate a 'breakthrough' US FDA deems Novartis' heart failure candidate a 'breakthrough'

    US FDA deems Novartis' heart failure candidate a 'breakthrough'. Serelaxin demonstrates ability to reduce shortness of breath and lower chance of dying. ... It also seems to boost kidney function and cardiac output. The RELAX-AHF data was first unveiled

More from news
Approximately 1 fully matching, plus 12 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Infographics